The KARDINAL trial demonstrated meaningful angiotensinogen reduction with a novel monthly injectable therapy.
Stacey E. Rosen, MD, FAHA
Advertisement
Articles by Stacey E. Rosen, MD, FAHA
Advertisement
Latest Updated Articles
Raising Awareness for Women's Cardiovascular CareApril 1st 2026
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
2
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
3
Why Some Patients Do Not Respond to GLP-1 Therapies
4
GIRE Combination Shows PFS Benefit in First-Line Metastatic Breast Cancer Treatment, Earning FDA Priority Review
5